Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
N Engl J Med
; 380(12): 1116-1127, 2019 03 21.
Article
in En
| MEDLINE
| ID: mdl-30779529
Full text:
1
Database:
MEDLINE
Main subject:
Carcinoma, Renal Cell
/
Antineoplastic Combined Chemotherapy Protocols
/
Antibodies, Monoclonal, Humanized
/
Programmed Cell Death 1 Receptor
/
Sunitinib
/
Axitinib
/
Kidney Neoplasms
Type of study:
Clinical_trials
/
Guideline
Limits:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
N Engl J Med
Year:
2019
Type:
Article